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ABSTRACT 
 
Background: To compare retinal vascular measurements, biomarkers of cerebral small vessel 
disease (SVD), in HIV positive men aged 50 years and above with similarly-aged HIV negative 
men and younger HIV positive men. 
Methods: We recruited white, non-diabetic men to a cross-sectional substudy of a larger cohort 
including three demographically-matched groups. Optic disc centred 45° colour fundus 
photographs were used to calculate central retinal arterial and venous calibre and the arterial-
venous ratio (AVR). We used univariate and multivariable linear regression to compare retinal 
vessel measurements in the three groups and to identify factors associated with AVR. 
Results: All HIV positive men were virologically suppressed. In a multivariable model, study 
group was not associated with AVR (adjusted β 0.010 for HIV positive men <50 [n=39] 
compared to HIV positive men aged >50 years [n=120], 95% CI -0.018 to 0.038, p=0.47; 
adjusted β 0.00002 for HIV negative men >50 years [n=52], 95% CI -0.022 to 0.022, p=0.99). 
Factors associated with lower AVR were systolic BP (adjusted β -0.009 per +10 mmHg, 95% CI -
0.015 to -0.003, p=0.002), history of stroke or transient ischemic attack (adjusted β -0.070, 95% 
CI -0.12 to -0.015, p=0.01), and recent recreational drug use (adjusted β -0.037, 95% CI -0.057 
to -0.018, p=0.0002). 
Conclusion: There were no differences in retinal vascular indices between HIV positive men 
aged >50 years and HIV negative men aged >50 years or HIV positive men aged <50 years, 
suggesting that HIV is not associated with an increased burden of cerebral SVD. 
 
Key words: HIV; retinal vessels; cerebral small vessel diseases.  
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ORIGINAL ARTICLE 
 
INTRODUCTION 
 
Life expectancy of people living with HIV (PLWH) now approaches that of the general 
population in many countries,1 and an increasing proportion of PLWH are over the age of 50 
years.2, 3 As the cohort ages, PLWH are at greater risk of comorbidities of older age such as 
cardiovascular disease, dementia, hypertension and type 2 diabetes. Cerebral small vessel 
disease (SVD) is associated with circulating inflammatory mediators and chronic immune 
activation in HIV negative populations.4, 5 Corresponding elevations of systemic inflammatory 
markers are reported in HIV even after virological suppression has been achieved.6, 7 It is 
plausible that HIV infection in middle and older age is associated with an increased risk of 
cerebral SVD. Cognitive impairment is reported to be highly prevalent in PLWH,8-10 and SVD is 
one potential mechanism for this.  
 
While epidemiological evidence suggests higher rates of large vessel ischaemic stroke in 
PLWH,11-18 SVD is likely to involve different pathological processes, and there have been fewer 
studies of SVD in HIV. One study of Dutch HIV positive men aged over 45 and HIV negative 
controls reported a greater burden of white matter hyperintensities of presumed vascular 
origin on brain magnetic resonance imaging 19 whereas two similar studies have found no 
association between HIV and neuroimaging measures of SVD,20, 21 and an autopsy study of SVD 
found similar negative results.22 The retina shares common embryological and physiological 
features with the central nervous system, and retinal vascular photography provides a cheaper, 
quicker and non-invasive way of indirectly measuring SVD. In cross-sectional studies in the 
general HIV-negative population, retinal vascular abnormalities (measured quantitatively by 
vessel diameters or qualitatively by as retinopathy) have been found to be independently 
associated with the extent of white matter hyperintensities 23, 24 and the presence of dementia in 
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people with hypertension.25 In cohorts, similar markers are independently associated with 
progression of cerebrovascular SVD 26 and ventricular enlargement.27 All of these 
neuropathological phenomena are associated with vascular cognitive impairment. 
 
To date, one published study has compared retinal vascular measures between PLWH and HIV 
negative controls.28 The study was conducted in Cape Town, South Africa and recruited mainly 
young adult Xhosa women (75% female, median age 40 years, 19% of the study sample aged 
over 50). There were no overall differences in arteriolar or venular diameter between PLWH 
and controls. A US-based study also looked at retinal measures in PLWH but did not include a 
seronegative control group.29 There is a need for studies employing retinal vascular 
measurements in other ethnic groups and in older, male participants who make up a larger 
proportion of PLWH in high-income countries and who are potentially at greatest risk of SVD. 
This study aimed to determine the association between HIV status, age and retinal vascular 
measurements in a United Kingdom-based sample of men living with HIV aged 50 years and 
over, and comparable groups of HIV negative men of similar age and HIV positive men aged 
under 50. 
 
METHODS 
 
Study population 
We conducted a cross-sectional ophthalmic substudy within the Pharmacokinetic and Clinical 
Observations in People over Fifty (POPPY) study, a multicentre UK and Ireland cohort study 
exploring a range of age-associated measures of health, service use and pharmacokinetic 
parameters in PLWH (ClinicalTrials.gov Identifier: NCT01737047). POPPY comprises three 
demographically matched groups (PLWH aged >50 years; PLWH aged <50 years; HIV negative 
persons aged >50 years) in a 2:1:1 ratio and includes both white and black African participants. 
White, male, non-diabetic participants were recruited between May 2014 and July 2016 in 
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London and Brighton, UK, in the same proportions as the parent cohort. Participants gave 
written, informed consent and the study was approved by the National Research Ethics Service 
Committee London – Camden & Islington, reference 14/LO/0316.  
 
Sample size calculations were based on observations from a previous study,28 where the 
arteriolar diameter in participants over 50 was mean 159.13, standard deviation (SD) 17.63 in 
PLWH and mean 166.24, SD 18.56 in HIV negative participants. Assuming that similar 
differences existed in the target population, and maintaining the 2:1:1 ratio, we aimed to include 
156 HIV positive men aged ≥50 years and 78 in each of the other two groups. This would 
achieve 80% power and an alpha level of 5% (STATA Statistics and Data Analysis software 
version 14.1, StataCorp, Texas, USA).  
 
Data collection 
Optic disc-centred 45 degree colour fundus photographs were taken at three study sites and 
uploaded to a central site (Moorfields Eye Hospital). In the first instance this was done with 
undilated pupils, and image quality was assessed in real time to determine the need for 
tropicamide-induced dilatation and repeat photography. Techniques for measurement and 
calculation of CRAE and central retinal vein equivalent (CRVE) and the arterial-venous ratio 
(AVR) have been reported previously.30, 31 Diameters of all vessels crossing a zone 0.5 to 1 disc 
diameter from the disc margin were assessed by the same certified and validated grader with 
image analysis software. The calibres of the six largest arterioles and the six largest venules 
were combined to estimate the calibre of the central retinal artery and vein. The AVR, a ratio of 
these two measures, was calculated for each eye. 
 
The POPPY cohort database provided clinical information relating to previous cardiovascular 
disease and risk factors, current and previous antiretroviral therapy use, latest CD4+ and CD8+ 
lymphocyte counts, anthropometric data, syphilis and hepatitis C virus serology, recreational 
6 
 
drug use and serum lipids. Framingham 10-year cardiovascular disease risk was calculated 
using the framingham STATA module.32, 33 
 
Statistical analysis 
After excluding images of insufficient quality, retinal measurements from one randomly-chosen 
eye per participant were compared between the three groups (HIV positive ≥50, HIV positive 
<50, HIV negative ≥50) using linear regression. PLWH who did not have a suppressed HIV-1 
viral load (<50 copies/mL) on antiretroviral therapy were excluded from analysis. Factors 
associated with AVR were determined in bivariate models. Variables considered included study 
group as three categories, linear continuous variables (body mass index, waist circumference, 
diastolic and systolic blood pressure, and concentrations of total, high density lipoprotein and 
low density lipoprotein cholesterol) and binary variables (smoking status, self-reported history 
of ischaemic heart disease, stroke or transient ischaemic attack [TIA], injection drug use, 
psychoactive recreational drug use in the past 6 months, hepatitis C antibody status, and 
previous syphilis). Study group and factors found to have at least a modest association (p<0.2) 
with AVR in bivariate models were analysed in multivariable linear regression models. 
 
Additional linear regression analyses including only HIV positive participants explored 
associations between AVR and HIV-specific factors (linear continuous variables of CD4+ and 
CD8+ lymphocyte counts and CD4:CD8 ratio, time since HIV diagnosis, time between diagnosis 
and first initiation of antiretroviral therapy, and total duration of antiretroviral therapy, and 
binary categorisation of current use of all antiretroviral drug classes as well as abacavir and 
tenofovir), adjusted for study group (older or younger than 50 years). Again, a multivariable 
model was constructed of all variables found to be at least weakly associated (p<0.2) with AVR 
in bivariate models. 
 
RESULTS 
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Participant characteristics 
In total 228 people were photographed. Of these, grading was successfully done on images from 
211 participants (411 eyes; 120 HIV positive aged >50 years; 39 HIV positive <50 years; 52 HIV 
negative >50 years). Reasons for exclusion of the other 17 were missing data (n=6), incorrect 
field definition used during photography (n=8), images too dark (n=2), and severe tilting of the 
optic disc (n=1). 
 
There were some differences between the three groups, such as a higher rate of current 
smoking in PLWH aged <50, more PLWH reporting a lifetime history of injection drug use, and 
more PLWH in the older group reporting a history of stroke or TIA, or being seropositive for 
previous or current syphilis and hepatitis C (Table 1). There were no significant differences in 
blood pressure, anthropometry or serum lipid concentrations between groups. Differences in 
10-year cardiovascular risk were commensurate with age. Recent recreational drug use was 
high in all three groups (>25% in the past 6 months). The most frequently reported recreational 
drugs were cannabis (16%), ketamine (15%), methamphetamine (“crystal meth”, 13%) and 
amphetamine (13%). The number of HIV positive patients receiving each antiretroviral therapy 
drug class did not differ between the older and younger groups (total number on nucleoside 
reverse transcriptase inhibitors, 138 [86.8%]; non-nucleoside reverse transcriptase inhibitors, 
82 [51.6%]; protease inhibitors, 76 [47.8%]; integrase inhibitors, 14 [8.8%]). 
 
Prior ocular conditions in the final sample included cytomegalovirus retinitis (n=1), 
acanthamoeba infection resulting in a prosthesis on that side (n=1), hyaline asteroidosis (n=1) 
and cataracts (n=2), all of which were in PLWH aged ≥50 years. An additional 17 patients 
(8.1%) with drusen were identified (11 PLWH aged ≥50 years, 1 PLWH aged <50 years, and 5 
HIV negative aged ≥50 years). 
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Comparison of retinal vascular measurements between study groups 
Among the 211 participants, the mean AVR was 0.72 (standard deviation [SD] 0.07), mean CRAE 
was 141 (SD 20.2) and mean CRVE was 197 (SD 28.1), with no differences on any variable 
between the three groups (p>0.3), or between the two groups aged ≥50 years (HIV positive and 
HIV negative; p>0.2) (Fig. 1). The difference between the mean AVR in HIV positive men aged 
>50 and the HIV negative men of the same age was small: 0.716 compared to 0.719, a difference 
of 0.0026 (95% confidence interval [CI] -0.018 to 0.023, p=0.81) or one quarter of the standard 
error of the difference. Where good quality images were obtained from both eyes (n=202), AVR 
was correlated between left and right eyes (R2 = 0.161 by linear regression) and there was no 
evidence of an overall difference between left and right on paired t-test (mean 0.73, SD 0.08 
[left] versus mean 0.73, SD 0.07 [right], p=0.88). 
 
In bivariate models (Fig. 2, broken lines), factors associated with lower AVR were higher 
systolic BP (β -0.0009 per +10 mmHg, 95% CI -0.0014 to -0.0003, p=0.004), higher diastolic BP 
(β -0.001 per +10 mmHg, 95% CI -0.0024 to -0.0003, p=0.01) and recent recreational drug use 
(β -0.031, 95% CI -0.051 to -0.011, p=0.002). Variables that were weakly associated with AVR, 
which were incorporated into the multivariable model, were a history of stroke or TIA (β -0.042, 
95% CI -0.095 to 0.01, p=0.11) and a history of syphilis (β -0.015, 95% CI -0.034 to 0.005, 
p=0.14).  
 
A multivariable model incorporating these variables, as well as study group, was then analysed 
(Fig. 2, solid lines). Systolic BP was included but diastolic BP was omitted because of collinearity 
(systolic BP had the stronger association of the two variables). Neither comparison group was 
associated with AVR when compared to HIV positive men aged >50 years (adjusted β 0.010 for 
HIV positive men <50 years, 95% CI -0.018 to 0.038, p=0.47; adjusted β 2.0×10-5 for HIV 
negative men >50 years, 95% CI -0.022 to 0.022, p=0.99). Factors associated with lower AVR in 
the multivariable model were systolic BP (adjusted β -0.009 per +10 mmHg, 95% CI -0.015 to -
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0.003, p=0.002), history of stroke or TIA (adjusted β -0.070, 95% CI -0.12 to -0.015, p=0.01), and 
recent recreational drug use (adjusted β -0.037, 95% CI -0.057 to -0.018, p=0.0002). Similar 
analyses (not shown) failed to show any association between the three study groups and either 
CRAE or CRVE. 
 
Association between HIV-related factors and retinal vascular measurements 
In the analysis of only PLWH (Fig. 3), adjusted for age group, there was an association between 
lower AVR and higher current CD4+ lymphocyte count (adjusted β -0.004 per +100 cells/mm3, 
95% CI -0.008 to 0, p=0.05) but no association with current CD8+ count, CD4:CD8 ratio, any 
specific antiretroviral drug or class, or any of the time spans analysed (years on or off 
antiretroviral therapy, or total time since diagnosis). 
 
DISCUSSION 
 
In this study of 159 HIV positive and 52 HIV negative men, we found no association between 
HIV status and retinal vascular measurements. This is in keeping with the findings of a similar 
study in a South African population.28 As expected, we found associations with hypertension and 
stroke history, as well as an association with recent recreational drug use. Within the group of 
PLWH, there was a smaller AVR in those with higher absolute CD4+ lymphocyte count which 
may indicate the influence of immune activation, although CD4+:CD8+ cell ratio was not 
associated. We did not observe any association between the duration of antiretroviral therapy 
and retinal arteriolar narrowing 28, although this was observed in the South African study. 
PLWH receiving ART in South Africa differ markedly in their clinical features from the UK HIV 
positive population, and the healthcare systems providing HIV care have evolved in different 
ways, so there are several plausible explanations for the differences in our observations, 
including possible collinearity between age and duration of treatment in the South African 
patient sample. 
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Retinal photography with measurement of vascular calibre is widely used in epidemiological 
studies and clinical monitoring. Abnormal retinal diameters and qualitative features of 
retinopathy are associated with an increased risk of numerous conditions in middle-aged or 
older HIV negative people, including neuroimaging features of SVD, cognitive impairment, 
stroke, cardiovascular disease, incident diabetes, metabolic syndrome and all-cause mortality.23-
27, 34-40 In a large Dutch study (n=5540), a decrease in AVR of 1 standard deviation (0.06 in that 
study) was associated with a 14% increase in the risk of stroke.40 This compares to an 8% 
increase in risk conferred by a 10 mm Hg increase in systolic BP in white Americans and 24% 
increase in stroke risk from the same increase in BP in black Americans.41  
 
In studies employing other measures of cerebral SVD, there is mixed evidence for whether the 
extent and severity of cerebrovascular disease is increased in PLWH. Earlier studies of mainly 
untreated HIV positive individuals using older neuroimaging techniques found little evidence of 
an association between HIV and white matter hyperintensities of presumed vascular origin.42, 43 
Furthermore, an autopsy study of HIV positive, hepatitis C virus positive and uninfected 
individuals found no association between cerebral SVD and HIV status.22 More recently, two 
other studies measuring the total volume of white matter hyperintensities, a standard 
quantitative measure of cerebral SVD,44 found no overall difference between HIV positive and 
HIV negative participants.20, 21 But two recent neuroimaging studies that have found an 
association between HIV status and small vessel disease include a recent Dutch study of men 
over 45 years of age, in which the total volume of white matter hyperintensities was greater in 
PLWH than in well-matched HIV negative study participants,19 and a larger French study using 
the Fazekas and Schmidt neuroradiological rating scale,45 which reported a higher prevalence of 
cerebral SVD in PLWH than in HIV negative controls [unpublished conference abstract].46 The 
control group in the latter study may not have been well-matched, however, thus introducing 
bias. 
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Our study focused on a specific demographic group, which may limit the generalisability of our 
findings to other settings. We chose to restrict on the basis of ethnic group and gender to 
eliminate the well-described and powerful confounding effects of these variables on vascular 
disease markers; the study would likely have been insufficiently powered to perform gender 
and ethnicity subgroup analyses. We chose an older male cohort because such individuals are at 
greater risk of vascular disease, and we targeted the predominant demographic and 
transmission risk group (white men who have sex with men) attending our local clinics and 
living with HIV in the UK and many high-income settings. The study by Pathai et al included a 
study sample that was different to ours, being of younger age, entirely Xhosa ethnic group and 
predominantly female, and they also found no association between HIV status and retinal 
vascular calibres.28 It is a strength of our study that the HIV negative controls had similar 
measured characteristics to the older HIV positive sample, and their attendance for sexual 
health and HIV testing at the same centres as the HIV positive groups should have reduced the 
effect of unmeasured confounders. 
 
The study’s sample size was smaller than planned and the participants were in middle age and 
therefore at lower risk of cerebrovascular disease than an older-aged group. However the 
difference observed between the HIV positive and HIV negative groups aged >50 was very small 
compared to the overall distribution of values, and despite the small sample the evidence for 
there being no true difference in retinal calibres on the basis of HIV status is strong. 
 
The results of this study contribute to the accumulated evidence so far in this field. In summary, 
this evidence does not consistently find HIV to be a risk factor for cerebral SVD. Of the PLWH 
aged >50, 24% had a 10-year risk of cardiovascular disease (Framingham model) of above 10% 
(the threshold above which the UK National Institute for Health and Care Excellence 
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recommends statin therapy for primary prevention).47 Our findings do not diminish the need for 
assessment and optimisation of individual patients’ cardiovascular risks. 
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FIGURE LEGENDS 
 
Figure 1. Retinal vascular indices, showing mean and standard error for all three groups. 
 
 
Footnotes: PLWH aged 50 years and above, squares (n=120); PLWH under 50 years, triangles 
(n=39); HIV negative aged 50 years and above, circles (n=52). Lower values of AVR and CRAE, 
and higher values of CRVE, are considered to be pathological. 
AVR, arterial-venous ratio; CRAE, central retinal artery equivalent; CRVE, central retinal vein 
equivalent.  
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Figure 2. Factors associated with arterial-venous ratio, showing unadjusted (broken lines) and 
adjusted (solid lines) coefficients. 
 
 
Footnotes: Multivariable estimates and 95% confidence intervals are shown. Leftward 
deflections in coefficient (negative values) indicate an association with lower AVR and more 
pathological change. Variables that were assessed in unadjusted models but are not shown here 
because p>0.2 were body mass index, waist circumference, lipids, smoking status, self-report of 
previous ischaemic heart disease, lifetime history of injection drug use and hepatitis C antibody 
status. 
AVR, arterial-venous ratio; BP, systolic blood pressure; PLWH, people living with HIV; TIA, 
transient ischaemic attack. 
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Figure 3. HIV-related factors associated with arterial-venous ratio, showing partially adjusted 
(broken lines) and fully adjusted (solid lines) coefficients 
 
 
Footnotes: Models include only HIV positive participants and are adjusted for study group (aged 
above or below 50). Estimates and 95% confidence intervals are shown. Leftward deflections in 
coefficient (negative values) indicate an association with lower AVR and more pathological 
change. Variables that were assessed in partially adjusted models but are not shown here 
because p>0.2 were CD4:CD8 ratio, years since HIV diagnosis, years between diagnosis and first 
initiation of antiretroviral therapy, total years of antiretroviral therapy, and current use of each 
antiretroviral drug class. 
AVR, arterial-venous ratio. 
 
 
